92 studies found for:    coronado
Show Display Options
Rank Status Study
1 Withdrawn TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Active, not recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Terminated Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
6 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
8 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
9 Recruiting Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Conditions: Hepatitis C;   Cirrhosis
Interventions: Drug: daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
10 Enrolling by invitation A Registry for Participants With Cirrhosis Who Achieved a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials
Condition: Hepatitis C Virus Infection
Intervention: Drug: Sofosbuvir
11 Recruiting A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Condition: Hepatitis C Virus
Interventions: Drug: ombitasvir/ABT-450/ritonavir;   Drug: Ribavirin
12 Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus
Interventions: Drug: ABT-493;   Drug: ABT-530;   Drug: Ribavirin (RBV)
13 Active, not recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   HCV
Interventions: Drug: ABT-493;   Drug: ABT-530
14 Active, not recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
15 Recruiting A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
Conditions: Liver Fibrosis;   Hepatic Fibrosis;   Liver Cirrhosis;   Hepatic Cirrhosis
Intervention: Drug: IDN-6556
16 Completed Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Interventions: Biological: NGM282;   Biological: Placebo
17 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platelet count);   Drug: avatrombopag (higher baseline platelet count);   Drug: placebo (higher baseline platelet count)
18 Recruiting Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Conditions: Acute Episode of Overt Hepatic Encephalopathy;   Hepatic Encephalopathy
Interventions: Drug: ornithine phenylacetate;   Drug: placebo intravenous infusion
19 Active, not recruiting Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
Condition: Liver Cirrhosis
Interventions: Drug: Placebo;   Drug: Rifaximin SSD 40 mg IR tablet;   Drug: Rifaximin SSD 80 mg IR tablet;   Drug: Rifaximin SSD 40 mg SER tablet;   Drug: Rifaximin SSD 80 mg SER tablet;   Drug: Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet
20 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years